...
首页> 外文期刊>Mediators of inflammation >Intraperitoneal Infusion of Mesenchymal Stem/Stromal Cells Prevents Experimental Autoimmune Uveitis in Mice
【24h】

Intraperitoneal Infusion of Mesenchymal Stem/Stromal Cells Prevents Experimental Autoimmune Uveitis in Mice

机译:间充质茎/基质细胞的腹膜内输注可防止小鼠实验性自身免疫葡萄膜炎

获取原文
获取原文并翻译 | 示例
           

摘要

Autoimmune uveitis is one of the leading causes of blindness. We here investigated whether intraperitoneal administration of human mesenchymal stem/stromal cells (hMSCs) might prevent development of experimental autoimmune uveitis (EAU) in mice. Time course study showed that the number of IFN-y- or IL-17-expressing CD4+ T cells was increased in draining lymph nodes (DLNs) on the postimmunization day 7 and decreased thereafter. The retinal structure was severely disrupted on day 21. An intraperitoneal injection of hMSCs at the time of immunization protected the retina from damage and suppressed the levels of proinflammatory cytokines in the eye. Analysis of DLNs on day 7 showed that hMSCs decreased the number of Thl and Thl7 cells. The hMSCs did not reduce the levels of IL-1/?, IL-6, IL-12, and IL-23 which are the cytokines that drive Thl/Thl7 differentiation. Also, hMSCs did not induce CD4+CD25+Foxp3+ cells. However, hMSCs increased the level of an immunoregulatory cytokine IL-10 and the population of IL-10-expressing B220+CD19+ cells. Together, data demonstrate that hMSCs attenuate EAU by suppressing Thl/Thl7 cells and induce IL-10-expressing B220+CD19+ cells. Our results support suggestions that hMSCs may offer a therapy for autoimmune diseases mediated by Thl/Thl7 responses.
机译:自身免疫性葡萄膜炎是失明的主要原因之一。我们在这里研究了人间充质茎/基质细胞(HMSCs)的腹膜内施用是否可以防止小鼠的实验性自身免疫葡萄膜炎(EAU)的发育。时间课程研究表明,在发酵后第7天的排出淋巴结(DLNS)中,IFN-Y或IL-17表达的CD4 + T细胞的数量增加,此后减少。视网膜结构在第21天严重破坏。免疫时,腹腔注射HMSCs受到损伤的视网膜,抑制了眼睛中促炎细胞因子的水平。第7天的DLN分析表明,HMSCs降低了THL和TH7细胞的数量。 HMSCs没有减少IL-1 /β,IL-6,IL-12和IL-23的水平,其是驱动THL / TH17分化的细胞因子。此外,HMSCs没有诱导CD4 + CD25 + Foxp3 +细胞。然而,HMSCs增加免疫调节细胞因子IL-10的水平和IL-10表达B220 + CD19 +细胞的群体。一起,数据表明HMSCs通过抑制THL / TH17细胞抑制EAU,并诱导IL-10表达B220 + CD19 +细胞。我们的研究结果支持HMSCs可以提供由THL / THL7答复介导的自身免疫疾病治疗的治疗。

著录项

  • 来源
    《Mediators of inflammation》 |2014年第6期|共1页
  • 作者

    Joo Youn Oh;

  • 作者单位

    Department of Ophthalmology Seoul National University Hospital Seoul 110-744 Republic of Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 病理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号